All In Biotech

Drug Trial Radar · NCT01636076

Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Randomized, Double-blind, 12-week Treatment, Parallel-group Study to Evaluate the Efficacy and Safety of QMF149 (150 µg/160 µg o.d.) Compared With Salmeterol Xinafoate/Fluticasone Propionate (50 µg/500 µg b.i.d.) in Patients With Chronic Obstructive Pulmonary Disease

Last checked: Nov 19, 2026Latest source record: Nov 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 629 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

629

Actual

Start

Nov 2012

Primary completion

Sep 2013

Study completion Sep 2013

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 10, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the efficacy, safety and pharmacokinetics of QMF149 delivered via Concept1 to salmeterol xinafoate/fluticasone propionate delivered via Accuhaler in adult patients with COPD

Conditions

  • COPD

Interventions

  • QMF149Drug

    delivered via Concept1 device

  • SalmeterolDrug

    delivered via Accuhaler®

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mixed Model for Repeated Measures (MMRM): Between-treatment Comparisons for Trough FEV1 (L) on Day 85Time frame: 12 weeks

Locations

115 sites in 18 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Concord, New South Wales, Australia

  • Novartis Investigative Site

    Kogarah, New South Wales, Australia

  • Novartis Investigative Site

    New Lambton Heights, New South Wales, Australia

  • Novartis Investigative Site

    Redcliffe, Queensland, Australia

  • Novartis Investigative Site

    Bedford Park, South Australia, Australia

  • Novartis Investigative Site

    Daw Park, South Australia, Australia

  • Novartis Investigative Site

    Woodville South, South Australia, Australia

  • Novartis Investigative Site

    Box Hill, Victoria, Australia

  • Novartis Investigative Site

    Fitzroy, Victoria, Australia

  • Novartis Investigative Site

    Franston, Victoria, Australia

  • Novartis Investigative Site

    Nedlands, Western Australia, Australia

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Halen, Belgium

  • Novartis Investigative Site

    Liège, Belgium

  • Novartis Investigative Site

    Pleven, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Stara Zagora, Bulgaria

  • Novartis Investigative Site

    Veliko Tarnovo, Bulgaria

  • Novartis Investigative Site

    Rousse, Bulgaria, Bulgaria

  • Novartis Investigative Site

    Varna, Bulgaria, Bulgaria

  • Novartis Investigative Site

    Copenhagen NV, Denmark

  • Novartis Investigative Site

    Odense C, Denmark

  • Novartis Investigative Site

    Hellerup, Denmark, Denmark

  • Novartis Investigative Site

    Hvidovre, Denmark, Denmark

  • Novartis Investigative Site

    Pori, Finland

  • Novartis Investigative Site

    Tampere, Finland

  • Novartis Investigative Site

    Turku, Finland, Finland

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Donaustauf, Germany

  • Novartis Investigative Site

    Frankfurt, Germany

  • Novartis Investigative Site

    Großhansdorf, Germany

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    Lübeck, Germany

  • Novartis Investigative Site

    Rüdersdorf, Germany

  • Novartis Investigative Site

    Witten, Germany

  • Novartis Investigative Site

    Berlin, Germany, Germany

  • Novartis Investigative Site

    Wiesbaden, Germany, Germany

  • Novartis Investigative Site

    Athens, Greece

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.